Compare L3Harris Technologies Inc (LHX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs Recursion Pharmaceuticals Inc — how do they compare? L3Harris Technologies Inc trades at $236.97 (market cap $44.12B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: L3Harris Technologies Inc is far larger — about 20.6× Recursion Pharmaceuticals Inc's market cap, and L3Harris Technologies Inc pays a 2.11% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| LHX | RXRX | |
|---|---|---|
Market Cap | $44.12B | $2.14B |
Volume | 1,202,852 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $378.48 | $6.79 |
52-Week Low | $233.63 | $2.84 |
Typical Hold Time | 56 Days | 23 Days |
Enterprise Value | $54.56B | $1.66B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $236.92, up 1.41% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with 7.34% net margin and $1.61B net income in 2025. Recent $6B THAAD contract win highlights defense sector strength, though multiple law firm investigations create investor uncertainty.
Outlook remains positive with analyst consensus target of $340 (44% upside), supported by defense budget tailwinds and projected 2026 revenue growth to $22.9B. Key risks include legal investigations and debt levels, but institutional buy ratings (73.5%) signal confidence in long-term defense contracting business model.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
